[Nutritional status and lifestyles of workers from two regions in Chile].

Sitagliptin: an oral agent for glucose control.

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.

Combination pharmacotherapy with incretins: what works best and when?

First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes.

Approach to the patient with prediabetes.

Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program.

Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial.

Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults.

Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study.

Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes.

Prevention of type 2 diabetes in women with previous gestational diabetes.

Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk.

Exenatide and pramlintide: new therapies for diabetes.